
Traditional diabetes care often relies on scheduled visits, medication plans and periodic glucose checks. Digital therapeutics, which use Artificial Intelligence (AI) and real-time health tracking, now offer patients more continuous, personalized support. Joe Kiani, founder of Masimo, sees this shift as a way to reduce the daily strain on patients while improving outcomes. As both approaches continue to develop, many are weighing how digital solutions stack up against conventional care in terms of long-term results and patient engagement.
While traditional care continues to play a role in long-term diabetes treatment, digital therapeutics is emerging as a new category of support. These software-based tools are designed to deliver clinically proven interventions and help patients manage their condition with greater consistency and personalization. These platforms use AI to monitor trends, deliver personalized insights and help patients make small, daily adjustments that support better outcomes over time.
How Standard Diabetes Care Works… Read more



